InnoCare Pharma (HKEX: 09969; SSE: 688428), today announced that the Journal of Autoimmunity has published results from a clinical study evaluating orelabrutinib, a BTK (Bruton’s tyrosine kinase) ...
A review article examines questions about sequencing treatments in light of recent developments in relapsed/refractory mantle cell lymphoma. Treatment approaches have shifted with the introduction of ...
The treatment landscape of chronic lymphocytic leukaemia has undergone a revolution in the past decade. Highly effective ...
With both a label expansion and a conversion to a full approval, Eli Lilly has earned the FDA’s go-ahead to act on the initial promise it saw with its BTK inhibitor Jaypirca (pirtobrutinib). Just ...
"It's the first study to show a significant difference between all three covalent BTK inhibitors," says Daniel A. Ermann, MD.
–– Fenebrutinib is an investigational, potent and highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS) ...
With a positive phase 3 trial in chronic lymphocytic leukemia (CLL), Eli Lilly hopes to convert Jaypirca’s unique accelerated approval—which allows the BTK inhibitor to be used following another drug ...
Panelists discuss how fixed-duration options like venetoclax plus obinutuzumab show promise in treating chronic lymphocytic leukemia (CLL) by offering defined treatment periods rather than indefinite ...
A new research perspective titled "Bruton's tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification" has been published in Oncotarget. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results